Compounds > armillaridin
Page last updated: 2024-12-07

armillaridin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

armillaridin: isolated from Armillaria mellea mycelium I; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51351607
CHEMBL ID1762764
CHEBI ID185923
MeSH IDM0128079

Synonyms (4)

Synonym
armillaridin
[(2r,2as,4as,7as,7br)-3-ormyl-2a-hydroxy-6,6,7b-trimethyl-1,2,4a,5,7,7a-hexahydrocyclobuta[e]inden-2-yl] 3-chloro-6-hydroxy-4-methoxy-2-methylbenzoate
CHEBI:185923
CHEMBL1762764
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sesquiterpenoidAny terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID589479Cytotoxicity against human Jurkat cells2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID589480Cytotoxicity against human HeLa cells2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID1183884Cytotoxicity against human MONO-MAC-6 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID589481Cytotoxicity against human K562 cells2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID1183883Cytotoxicity against human THP1 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1183885Cytotoxicity against human primary monocytes after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID589478Cytotoxicity against human MCF7 cells2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID1183886Cytotoxicity against human K562 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1183887Cytotoxicity against human HeLa cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.21106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
carbonyl cyanide m-chlorophenyl hydrazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.		2.110hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.1110
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.4820antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
staurosporine
[no description available]		2.110indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
diacetyldichlorofluorescein
diacetyldichlorofluorescein: stable storage form of dichlorofluorescein		2.1110
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		2.4820actinomycinmutagen
sesquiterpenes
[no description available]		3.1550
pretubulysin
pretubulysin: from myxobacteria; structure in first source		2.110
3-methyladenine
N3-methyladenine: structure in first source		2.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatocellular Carcinoma
[description not available]		07.2110
Cancer of Liver
[description not available]		02.2110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.2110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.2110
Granulocytic Leukemia, Chronic
[description not available]		02.1310
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		02.1310